Скачать или смотреть Oscar Health: Profit Miracle or House of Cards? (2026 Verdict)

Welcome back to Iron Financial, where we forge stronger portfolios by cutting through the market’s noise. Today, we are putting Oscar Health (NYSE: OSCR) under the hydraulic press.

After a "reset year" in 2025 that saw the company bleed $443 million, management is betting the house on a 2026 profit turnaround. We drill down into the massive membership spike to 3.4 million lives, the 95.4% medical loss ratio (MLR) that shocked the street in Q4, and the "Agentic AI" that Mark Bertolini claims is the future of healthcare efficiency.

Is the new $475 million credit facility a solid foundation for growth, or just a temporary brace for a collapsing structure? We break down the numbers, the risk adjustments, and the shifting metal tiers to tell you if OSCR is a trap or the ultimate turnaround play.

In this video:

The 2025 Damage Report: Analyzing the $396M operating loss.

The 2026 Blueprint: Can they really hit $19 Billion in revenue?

The Skeptic’s Corner: Why "Passive Renewals" are a massive risk.

The Final Verdict: Buy, Sell, or Watch?